GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

BNC Korea Co 256840.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

2,210

+1.14%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About BNC Korea Co

Its shares trade on KOSDAQ under the ticker 256840.KQ. It has been listed since 28 December 2016. In the fiscal year to 31 December 2025, it reported revenue of ₩95.90bn and net income of ₩2.84bn. At that date it held total assets of ₩277.99bn and shareholders' equity of ₩233.70bn.

BNC Korea Co., Ltd. researches and develops strategic application products which include medical devices, pharmaceuticals, and cosmetic products containing physiologically active substances by processing hyaluronic acid and collagen. The company is headquartered in Daegu, Daegu. The company went IPO on 2016-12-28. The firm's main products include hyaluronic acid (HA) fillers, collagen wound dressings, antiadhesion materials and collagen tissue supplements, and others. In addition, the Company produces and sells cosmetics, medicines and medical devices, among others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
28 Dec 2016
Employees
172

Leadership

Pay as last reported

  • Mr. Wan Gyu ChoiChief Executive Officer, Director
  • Mr. Gi Sin KangAssistant Managing Director
  • Mr. Jae Myeong YangInternal Auditor
  • Mr. Si Yeong HwangDirector
  • Mr. Seong Won HongNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Daegu, South Korea
  • Focus on biotechnology within health care sector
  • Offers diverse products including HA fillers and collagen dressings

Weaknesses

  • Limited employee count of 172
  • IPO date of 2016-12-28 indicates a relatively young company
  • No mention of international market presence

Opportunities

  • Growing demand for biotechnology products in health care
  • Potential for expansion into cosmetic and pharmaceutical markets
  • Opportunity to leverage hyaluronic acid and collagen applications

Threats

  • Competition from established biotechnology firms
  • Dependence on specific product lines like HA fillers
  • Untrusted source description may lead to inaccurate information

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.